Sep 6, 2024

Featuring perspectives from Prof Peter Schmid and Dr Sara M Tolaney, including the following topics:

• Introduction: Pharmacology and Sequencing of Antibody-Drug Conjugates (ADCs) in Metastatic Breast Cancer (mBC) (0:00)
• Expanding Role of TROP2-Directed ADCs in mBC Management — Dr Tolaney (21:42)
• Other Targets for ADC...

Sep 6, 2024

Inside the Issue: Integrating Antibody-Drug Conjugates into the Management of HR-Positive and Triple-Negative Metastatic Breast Cancer | Faculty Presentation 2: Other Targets for ADC Therapy in mBC — Professor Peter Schmid, FRCP, MD, PhD

CME information and select...

Sep 6, 2024

Inside the Issue: Integrating Antibody-Drug Conjugates into the Management of HR-Positive and Triple-Negative Metastatic Breast Cancer | Faculty Presentation 1: Expanding Role of TROP2-Directed Antibody-Drug Conjugates (ADCs) in Metastatic Breast Cancer (mBC) Management — Sara M Tolaney, MD, MPH

CME information and...

Aug 29, 2024

Featuring a slide presentation and related discussion from Dr Priyanka Sharma, including the following topics:

• Biomarker Assays in the Identification and Prognostication of Patients with Breast Cancer (0:00)
• Utility of Circulating Tumor DNA in the Prognostication of Localized Breast Cancer (24:28)
• Treatment of...

Aug 23, 2024

Featuring an interview with Prof Giuseppe Curigliano, including the following topics:

• Counseling patients with newly diagnosed metastatic breast cancer (mBC); role of patient-reported outcomes and advocacy (0:00)
• Individualized selection of up-front therapy for patients with HR-positive, HER2-negative mBC (6:02)